Maximizing the Value of Real-World Data and Real-World Evidence to Accelerate Healthcare Transformation in China: Summary of External Advisory Committee Meetings

• Published in: Pharmaceutical medicine Vol. 38; no. 3; pp. 157 - 166
• Main Authors: Sun, Feng, Bedenkov, Alexander, Liu, Bi-Cheng, Yang, Jiefu, Xu, Jin-fu, Ji, Linong, Zhou, Min, Zhang, Shaosen, Li, Xinli, Song, Yuanlin, Chen, Pingyan, Moreno, Carmen
• Format: Journal Article
• Language: English
• Published: Cham Springer International Publishing 01-05-2024; Springer Nature B.V
• Subjects: Advisory Committees - organization & administration; Alliances; Biomedical and Life Sciences; Biomedicine; China; Clinical medicine; Clinical trials; Collaboration; Cost control; Current Opinion; Delivery of Health Care; Digital technology; Electronic health records; Health Services Accessibility; Humans; Medical equipment; Meetings; Pharmaceutical Sciences/Technology; Pharmacology/Toxicology; Pharmacotherapy; Stakeholder Participation; Stakeholders; China; South Korea; United States > US; Europe
• ISSN: 1178-2595; 1179-1993
• DOI: 10.1007/s40290-024-00520-3

Use of real-world data (RWD) is gaining wide attention. To bridge the gap between diverse healthcare stakeholders and to leverage the impact of Chinese real-world evidence (RWE) globally, a multi-stakeholder External Advisory Committee (EAC) and EAC meetings were initiated, aiming to elucidate the current and evolving RWD landscape in China, articulate the values of RWE in ensuring Chinese patients’ equitable access to affordable medicines and solutions, and identify strategic opportunities and partnerships for expansion of RWE generation in China. Chinese and international experts who are clinicians and academic researchers were selected as EAC members based on their professional background and familiarity with RWD/RWE. Three EAC meetings were held quarterly in 2023. Various topics were presented and discussed for insights and suggestions. Nine experts from China, one from South Korea, and two from Europe were selected as EAC members and attended these meetings. Experts’ presentations were summarized by theme, including the RWD landscape and RWE enablement in China, as well as global development of a patient-centric ecosystem. Experts’ insights and suggestions on maximizing the RWD/RWE value to accelerate healthcare transformation in China were collected. We concluded that though data access, sharing, and quality are still challenging, RWD is developing to support evidence generation in the medicinal product lifecycle, inform clinical practice, and empower patient management in China. RWD/RWE creates value, accelerates healthcare transformation, and improves patient outcomes. Fostering a patient-centric ecosystem across healthcare stakeholders and maintaining global partnerships and collaboration are essential for unlocking the power of RWD/RWE.